Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 22, 2016 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at the Lotte New York Palace Hotel, New York.
Event: 28th Annual Piper Jaffray Healthcare Conference
Date: Wednesday, November 30, 2016
Time: 1:30 PM ET
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform.
MEDIA CONTACTS: Jennifer Paganelli W2O Group for CRISPR 347-658-8290 [email protected] INVESTOR CONTACT: Chris Brinzey Westwicke Partners for CRISPR 339-970-2843 [email protected]
